Brisbane, CA–(business wire)–Johnson & Johnson (NYSE: JNJ) (the Company) today announced the opening of its San Francisco Bay Campus, a state-of-the-art research and development (R&D) facility in the Bay Area of one of the world’s most established global companies. opened. A hub of innovation and entrepreneurship. The approximately 200,000-square-foot facility will house up to 400 employees, more than doubling Johnson & Johnson’s R&D presence in the Bay Area. The campus bridges critical scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation, and Johnson & Johnson Technology. This will further integrate the company into the Bay Area’s innovation ecosystem, enhance and increase collaboration with innovators, and accelerate growth.
Joaquin Duato, CEO of Johnson & Johnson, said: At this campus, a talented team leverages diverse experience and expertise to tackle society’s greatest health challenges and create a better future for patients. ”
The focus of research and development at the new facility spans Janssen’s therapeutic areas and critical capabilities, including new technologies for gene and RNA therapy, new treatments and approaches for retinal and infectious diseases, artificial It includes advanced data science including intelligence and machine learning. Placing expertise on site enables the expansion of our world-class discovery engine and industry-leading pipeline.
“Our new state-of-the-art science facility in the Bay Area will further strengthen our research and development capabilities and transform the way we discover, develop and deliver innovative medicines more quickly and efficiently. By integrating digital health, we aim to accelerate the growth of our best-in-class portfolio and bring better health to people around the world.” Janssen Research & Development, LLC Infectious Diseases Division Campus and Global Treatments area manager.
Since 2014, the Johnson & Johnson Innovation Center in California has invested and collaborated to accelerate early-stage healthcare innovation with academic and industry partners in the Bay Area and the greater California ecosystem. have promoted. Francisco has built strong relationships with entrepreneurs, scientists and investors to continue enabling them to support and invest in highly differentiated innovations that extend and improve lives everywhere. Additionally, given the convergence of healthcare and technology in the region, the company has increased its focus on the Johnson & Johnson Technology organization and its ability to create innovative digital solutions that advance human health. Strengthen.
Building on Johnson & Johnson’s long-standing commitment to leveraging its expertise and resources to reduce the environmental footprint of its operations, the Bay Area hub is designed as a high-performing green campus and a healthy environment. reinforces our pledge to be responsible stewards of the , a more sustainable future. The new site aims to achieve LEED (Energy & Environmental Design) Silver Leadership Certification, the world’s most widely used green building rating system.
About Johnson & Johnson
At Johnson & Johnson, we believe that health is the foundation of vibrant lives, thriving communities and progress. That’s why, for over 135 years, we’ve aimed to keep people of all ages and in all life stages healthy. As the world’s largest and broadest-based healthcare company today, we are committed to using our reach and scale for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. and ingenuity to dramatically change the trajectory of human health. For more information, please visit www.jnj.com. Follow us at @JNJNews.
About The Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we are creating a future where disease is a thing of the past. We are the pharmaceutical company of Johnson & Johnson, working tirelessly to create a future for patients around the world by fighting disease with science, improving access with ingenuity, and healing despair from the heart. continue. We focus on the areas of medicine where we can make the biggest difference. Cardiovascular, metabolic, retina. immunology; infectious diseases and vaccines; neuroscience; oncology; and pulmonary hypertension. For more information, please visit www.janssen.com. Follow us at @JanssenGlobal. Janssen Research & Development, LLC is part of Johnson & Johnson’s Janssen Pharmaceutical Companies.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC spans the pharmaceutical, medical device and consumer health sectors, accelerating early stage innovative solutions by catalyzing the best ideas anywhere in the world. This includes a wide range of customized trading structures, company formation, incubation and start-up services, capital investment and other innovative business models aimed at meeting the diverse needs of entrepreneurs, scientists and researchers. It is achieved by leveraging deep scientific competencies combined with tools. start-up. Our goal is to help Life Sciences and health technology innovations succeed through collaboration and partnerships with the global ecosystem so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to work with us at www.jnjinnovation.com.
About Johnson & Johnson Technologies
Johnson & Johnson Technology solves big problems in healthcare through technology and digital innovation. We are using data science, algorithms, artificial intelligence, robotics, and other digital solutions to transform patients’ lives the way doctors use scalpels. From getting patients to therapy, accelerating vaccine development, and enabling employees to work seamlessly from anywhere, our digital tools bring novelty, dexterity and ease of use to our products. . Guided by our beliefs, we unlock the power of technology to drive greater access, equity and sustainability, shaping the future of healthcare in ways only we can.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Among other things, it relates to future operating and financial results, product development, market position and business strategy. Readers are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. Actual results may differ materially from Janssen Research & Development, LLC’s expectations and projections if the underlying assumptions are inaccurate or if known or unknown risks or uncertainties materialize. Risks and uncertainties include, but are not limited to: Economic factors such as interest rate and exchange rate fluctuations. Competition, such as technological advances, new products, and patents issued by competitors. Challenges inherent in new product research and development, such as the uncertainty of clinical success and obtaining regulatory approval. uncertainty of commercial success of new and existing products; Challenges to Patents; Effects of Patent Expiration. our ability to successfully execute our strategic plans; Impact of business combinations and divestitures. Manufacturing problems or delays internally or within the supply chain. Concerns about product efficacy or safety leading to product recalls or regulatory action. Serious adverse litigation or government action, including those related to product liability claims. changes in applicable laws and regulations, including tax laws and global health care reform; Trends in medical cost containment. Changes in purchaser behavior and spending patterns for healthcare products and services. Financial instability and sovereign risk in the international economy and legal system. Increased scrutiny of the healthcare industry by government agencies. Our ability to meet the conditions necessary to complete the separation of our Consumer Health business in a timely or complete manner. our ability to successfully separate our consumer health business and realize the expected benefits from the separation; New Consumer Health Company’s ability to succeed as an independent, publicly traded company. Risks associated with the impact of the COVID-19 global pandemic. For example, the scope and duration of the outbreak, government actions and the restrictive measures implemented in response, significant delays and cancellations of medical procedures, supply chain disruptions, and other impacts on businesses. , or our ability to implement business continuity plans as a result of the COVID-19 pandemic. A detailed list and description of these risks, uncertainties and other factors is set forth in Johnson & Johnson’s Annual Report on Form 10-K for the year ended January 2, 2022. It is listed. and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Report on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or upon request from Johnson & Johnson. Any forward-looking statements made in this release speak only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.